Partnership will help non-GLP evaluation of Sartorius’ tools with customer products and for internal R&D.

Sartorius Stedim Biotech entered into an agreement with WuXi AppTec to cooperate on viral-clearance studies. WuXi AppTec will provide the relevant viruses, materials, and methodologies to Sartorius Stedim Biotech for use in conducting non-GLP viral-clearance testing of its technologies with customer products and for supporting its own R&D.

Sartorius Stedim Biotech markets an orthogonal and fully integrated three-step viral-clearance platform to the biopharmaceutical industry. To further support its customers and to meet anticipated regulatory expectations, Sartorius says that it has built an in-house laboratory for non-GLP viral clearance testing of its technologies.

Previous articleThermo Fisher Scientific Bolsters India Presence with Acquisition of Chemito Franchises
Next articleGSK and the Immune Disease Institute in Boston Sign Five-Year $25M Collaboration